Publicaciones en las que colabora con Rafael Enríquez de Salamanca Lorente (23)

2024

  1. Exploring current and emerging therapies for porphyrias

    Liver International, Vol. 44, Núm. 9, pp. 2174-2190

  2. Porfirias.

    Medicina interna (Elsevier España), pp. 1865-1873

2023

  1. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2021

  1. Acute intermittent porphyria, givosiran, and homocysteine

    Journal of Inherited Metabolic Disease

2020

  1. Porfirias

    Medicina interna [19ª ed.] (Elsevier España)

2018

  1. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria

    Human Gene Therapy, Vol. 29, Núm. 4, pp. 480-491

2015

  1. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria

    Journal of Proteomics, Vol. 127, pp. 377-385

2012

  1. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

    Journal of translational medicine, Vol. 10, pp. 122

2009

  1. Epidermal growth factor receptor ligands in murine models for erythropoietic protoporphyria: Potential novel players in the progression of liver injury

    Cellular and Molecular Biology, Vol. 55, Núm. 1, pp. 29-37

  2. Identification and characterization of HMBS gene mutations in Spanish patients with acute intermittent porphyria

    Cellular and Molecular Biology, Vol. 55, Núm. 2, pp. 55-63

  3. Induction of hepatic aminolevulinate acid synthetase activity by isoflurane in a genetic model for erythropoietic protoporphyria

    Cellular and Molecular Biology, Vol. 55, Núm. 1, pp. 38-44

2008

  1. Bone marrow transplantation into hemochromatotic mice decreases hepatic and duodenal iron overload

    International Journal of Biochemistry and Cell Biology, Vol. 40, Núm. 1, pp. 135-146

2007

  1. Molecular heterogeneity of familial porphyria cutanea tarda in Spain: Characterization of 10 novel mutations in the UROD gene

    British Journal of Dermatology, Vol. 157, Núm. 3, pp. 501-507

2001

  1. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells

    Gene Therapy, Vol. 8, Núm. 8, pp. 618-626

2000

  1. Laboratory approximation to the diagnosis and typification of porphyria

    Anales de medicina interna (Madrid, Spain : 1984), Vol. 17, Núm. 11, pp. 609-613

1999

  1. Nonsynergic effect of ethanol and lead on heme metabolism in rats

    Ecotoxicology and Environmental Safety, Vol. 43, Núm. 1, pp. 98-102

1997

  1. Reduced aminolevulinate dehydrase activity in rats with functional renal failure induced by cyclosporin A

    Experimental Nephrology, Vol. 5, Núm. 4, pp. 323-329

  2. Reduced aminolevulinic dehydrase activity with increased blood porphyrins in experimental chronic renal failure

    Experimental Nephrology, Vol. 5, Núm. 1, pp. 95-99

1996

  1. Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis

    Journal of the American Society of Nephrology, Vol. 7, Núm. 5, pp. 774-779

  2. Prevalencia de porfiria cutánea tarda en Madrid y asociación entre la porfirinuria y el consumo de etanol en un modelo de regresión lineal múltiple

    Medicina Clinica, Vol. 107, Núm. 16, pp. 614-616